WIXELA INHUB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for WIXELA INHUB (WIXELA INHUB).
Wixela Inhub is an inhaled corticosteroid (fluticasone propionate) and long-acting beta2-adrenergic agonist (salmeterol) combination. Fluticasone propionate reduces inflammation by binding to glucocorticoid receptors, inhibiting pro-inflammatory mediators. Salmeterol stimulates beta2-receptors in bronchial smooth muscle, leading to bronchodilation via activation of adenylate cyclase and increased cAMP.
| Metabolism | Fluticasone propionate is primarily metabolized by CYP3A4. Salmeterol is metabolized by hydroxylation via CYP3A4 and to a lesser extent by CYP2D6, and undergoes extensive first-pass metabolism. |
| Excretion | Primarily renal excretion (70-80%) as unchanged drug; biliary/fecal (20-30%) as parent and metabolites. |
| Half-life | Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged (up to 30-50 hours) in renal impairment. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 10 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Inhalation: approximately 30-40% systemic bioavailability; oral: less than 5% due to first-pass metabolism. |
| Onset of Action | Inhalation: 15-30 minutes for bronchodilation. |
| Duration of Action | Duration of bronchodilation is 12 hours; clinical effect lasts 12 hours with twice-daily dosing. |
2 inhalations (total dose 50 mcg indacaterol/110 mcg glycopyrrolate) once daily via oral inhalation.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution; not recommended due to limited data. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B. Not recommended for Child-Pugh C due to lack of data. |
| Pediatric use | Not indicated for pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment; use with caution due to potential for increased anticholinergic adverse effects and reduced renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for WIXELA INHUB (WIXELA INHUB).
| Breastfeeding | No human data; M/P ratio unknown; excreted in animal milk; risk to nursing infant cannot be excluded; contraindicated during breastfeeding. |
| Teratogenic Risk | Pregnancy Category N; no adequate human studies; animal studies not conducted; first trimester: unknown risk; second and third trimesters: unknown risk; potential for fetal harm based on drug class (prostaglandin analog); contraindicated in pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Wixela Inhub is contraindicated in asthma without concomitant use of a long-term asthma control medication. In pediatric and adolescent patients with asthma, LABAs should only be used as additional therapy for those not adequately controlled on other asthma controller medications or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
| Serious Effects |
["Status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures","Primary treatment of acute bronchospasm","Severe hypersensitivity to milk proteins or any component of the product","Use in asthma without concomitant use of a long-term asthma control medication (LACA)"]
| Precautions | ["Risk of asthma-related death associated with LABAs","Increased risk of pneumonia in patients with COPD","Adrenal insufficiency with corticosteroid use","Systemic corticosteroid withdrawal symptoms","Candidiasis of mouth and pharynx","Paradoxical bronchospasm","Hypersensitivity reactions including anaphylaxis","Cardiovascular effects: increased blood pressure, tachycardia, QT prolongation","Hypokalemia and hyperglycemia with high doses","Decreased bone mineral density with long-term corticosteroid use","Glaucoma and cataracts with corticosteroid use","Growth suppression in pediatric patients","Ketoacidosis in diabetic patients"] |
Loading safety data…
| Monitor for uterine hyperstimulation and fetal distress if used inadvertently in pregnancy; no routine monitoring indicated. |
| Fertility Effects | May impair fertility due to prostaglandin-mediated effects on ovulation and implantation; reversible upon discontinuation. |